본문 바로가기
KERD
논문KCI 등재

Comparison of clinical practice guidelines for the management of chronic hepatitis B: When to start, when to change, and when to stop

Ji Hoon Kim|Jeong-Hoon Lee|Jun Yong Park|Eileen L. Yoon|Sae Hwan Lee|Hyun Woong Lee|Jung Hyun Kwon|Dong Hyun Sinn|Hana Park|Hyung Joon Yim
대한간학회 (The korean Association for the Study of the Liver)|2020.10|Clinical and Molecular Hepatology|제26권 제4호|pp. 411-429|DOI 10.3350/cmh.2020.0049

2

조회

0

다운로드

9

인용

0

참고문헌

키워드

ChronicHepatitis BClinical practice guidelinesHepatitis B virus

초록

Clinical practice guidelines are important for guiding the management of specific diseases by medical practitioners, trainees, and nurses. In some cases, the guidelines are utilized as a reference for health policymakers in controlling diseases with a large public impact. With this in mind, practice guidelines for the management of chronic hepatitis B (CHB) have been developed in the United States, Europe, and Asian-Pacific regions to suggest the best-fit recommendations for each social and medical circumstance. Recently, the Korean Association for the Study of the Liver published a revised version of its clinical practice guidelines for the management of CHB. The guidelines included updated information based on newly available antiviral agents, the most recent opinion on the initiation and cessation of treatment, and updates for the management of drug resistance, partial virological response, and side effects. Additionally, CHB management in specific situations was comprehensively revised. This review compares the similarities and differences among the various practice guidelines to identify unmet needs and improve future recommendations.

Abstract

Clinical practice guidelines are important for guiding the management of specific diseases by medical practitioners, trainees, and nurses. In some cases, the guidelines are utilized as a reference for health policymakers in controlling diseases with a large public impact. With this in mind, practice guidelines for the management of chronic hepatitis B (CHB) have been developed in the United States, Europe, and Asian-Pacific regions to suggest the best-fit recommendations for each social and medical circumstance. Recently, the Korean Association for the Study of the Liver published a revised version of its clinical practice guidelines for the management of CHB. The guidelines included updated information based on newly available antiviral agents, the most recent opinion on the initiation and cessation of treatment, and updates for the management of drug resistance, partial virological response, and side effects. Additionally, CHB management in specific situations was comprehensively revised. This review compares the similarities and differences among the various practice guidelines to identify unmet needs and improve future recommendations.

참고문헌 (98)

  1. Schweitzer A, "Estimations of worldwide prevalence of chronic hepatitis B virus infection : a systematic review of data published between 1965 and 2013", Lancet, 386, pp.1546~1555 (2015)
  2. Chae HB, "Current status of liver diseases in Korea: hepatitis B", Korean J Hepatol, 15(Suppl 6), pp.S13~S24 (2009)
  3. Yim HJ, "Natural history of chronic hepatitis B virus infection : what we knew in 1981 and what we know in 2005", Hepatology, 43(2 Suppl 1), pp.S173~S181 (2006)
  4. Lilian Yan Liang, "Unmet need in chronic hepatitis B management", Clinical and Molecular Hepatology, 25(2), pp.172~180 (2019), 대한간학회
  5. Tang LSY, "Chronic hepatitis B infection : a review", JAMA, 319, pp.1802~1813 (2018)
  6. Terrault NA, "Update on prevention, diagnosis, and treatment of chronic hepatitis B : AASLD 2018 hepatitis B guidance", Hepatology, 67, pp.1560~1599 (2018)
  7. European Association for the Study of the Liver, "EASL 2017 clinical practice guidelines on the management of hepatitis B virus infection", J Hepatol, 67, pp.370~398 (2017)
  8. Sarin SK, "Asian-Pacific clinical practice guidelines on the management of hepatitis B : a 2015 update", Hepatol Int, 10, pp.1~98 (2016)
  9. Korean Association for the Study of the Liver (KASL), "KASL clinical practice guidelines for management of chronic hepatitis B", Clinical and Molecular Hepatology, 25(2), pp.93~159 (2019), 대한간학회
  10. Park HN, "Upper normal threshold of serum alanine aminotransferase in identifying individuals at risk for chronic liver disease", Liver Int, 32, pp.937~944 (2012)
  11. Park JY, "High prevalence of significant histology in asymptomatic chronic hepatitis B patients with genotype C and high serum HBV DNA levels", J Viral Hepat, 15, pp.615~621 (2008)
  12. Shim JJ, "Serum alanine aminotransferase level and liver-related mortality in patients with chronic hepatitis B : a large national cohort study", Liver Int, 38, pp.1751~1759 (2018)
  13. Kim GA, "High risk of hepatocellular carcinoma and death in patients with immunetolerant-phase chronic hepatitis B", Gut, 67, pp.945~952 (2018)
  14. Grace Lai-Hung Wong, "Management of chronic hepatitis B patients in immunetolerant phase: what latest guidelines recommend", Clinical and Molecular Hepatology, 24(2), pp.108~113 (2018), 대한간학회
  15. Livingston SE, "Clearance of hepatitis B e antigen in patients with chronic hepatitis B and genotypes A, B, C, D, and F", Gastroenterology, 133, pp.1452~1457 (2007)
  16. Hsu YS, "Longterm outcome after spontaneous HBeAg seroconversion in patients with chronic hepatitis B", Hepatology, 35, pp.1522~1527 (2002)
  17. Korean Association for the Study of the Liver, "KASL clinical practice guidelines : management of chronic hepatitis B", Clin Mol Hepatol, 22, pp.18~75 (2016)
  18. Funk ML, "World-wide epidemiology of HBeAg-negative chronic hepatitis B and associated precore and core promoter variants", J Viral Hepat, 9, pp.52~61 (2002)
  19. Lok AS, "Mutations in the pre-core region of hepatitis B virus serve to enhance the stability of the secondary structure of the pre-genome encapsidation signal", Proc Natl Acad Sci U S A, 91, pp.4077~4081 (1994)
  20. Croagh CM, "Increasing hepatitis B viral load is associated with risk of significant liver fibrosis in HBeAg-negative but not HBeAg-positive chronic hepatitis B", Liver Int, 30, pp.1115~1122 (2010)
  21. Chen YC, "Prognosis following spontaneous HBsAg seroclearance in chronic hepatitis B patients with or without concurrent infection", Gastroenterology, 123, pp.1084~1089 (2002)
  22. Kim GA, "HBsAg seroclearance after nucleoside analogue therapy in patients with chronic hepatitis B : clinical outcomes and durability", Gut, 63, pp.1325~1332 (2014)
  23. Iloeje UH, "Predicting cirrhosis risk based on the level of circulating hepatitis B viral load", Gastroenterology, 130, pp.678~686 (2006)
  24. Chen CJ, "Risk of hepatocellular carcinoma across a biological gradient of serum hepatitis B virus DNA level", JAMA, 295, pp.65~73 (2006)
  25. Liaw YF, "Lamivudine for patients with chronic hepatitis B and advanced liver disease", N Engl J Med, 351, pp.1521~1531 (2004)
  26. Chang TT, "Long-term entecavir therapy results in the reversal of fibrosis", cirrhosis and continued histological improvement in patients with chronic hepatitis B, 2010, pp.52, 886~893
  27. Cho H, "Entecavir and tenofovir reduce hepatitis B virus-related hepatocellular carcinoma recurrence more effectively than other antivirals", J Viral Hepat, 25, pp.707~717 (2018)
  28. Kim WR, "Impact of long-term tenofovir disoproxil fumarate on incidence of hepatocellular carcinoma in patients with chronic hepatitis B", Cancer, 121, pp.3631~3638 (2015)
  29. Marcellin P, "Regression of cirrhosis during treatment with tenofovir disoproxil fumarate for chronic hepatitis B : a 5-year open-label follow-up study", Lancet, 381, pp.468~475 (2013)
  30. Kim MN, "Increased risk of hepatocellular carcinoma in chronic hepatitis B patients with transient elastography-defined subclinical cirrhosis", Hepatology, 61, pp.1851~1859 (2015)
  31. Lok AS, "Chronic hepatitis B : update 2009", Hepatology, 50, pp.661~662 (2009)
  32. Chang Y, "Nucleos(t)ide analogue treatment for patients with hepatitis B virus(HBV)e antigen-positive chronic HBV genotype C infection : a nationwide, multicenter, retrospective study", J Infect Dis, 216, pp.1407~1414 (2017)
  33. 송병철, "Is it necessary to delay antiviral therapy for 3.6 months to anticipate HBeAg seroconversion in patients with HBeAg-positive chronic hepatitis B in endemic areas of HBV genotype C?", Clinical and Molecular Hepatology, 20(4), pp.355~360 (2014), 대한간학회
  34. Wong VW, "Entecavir treatment in patients with severe acute exacerbation of chronic hepatitis B", J Hepatol, 54, pp.236~242 (2011)
  35. Cao Z, "A potent hepatitis B surface antigen response in subjects with inactive hepatitis B surface antigen carrier treated with pegylated-interferon alpha", Hepatology, 66, pp.1058~1066 (2017)
  36. Sinn DH, "Hepatocellular carcinoma risk in chronic hepatitis B virus-infected compensated cirrhosis patients with low viral load", Hepatology, 62, pp.694~701 (2015)
  37. Li WC, "Peginterferon alpha-based therapy for chronic hepatitis B focusing on HBsAg clearance or seroconversion : a meta-analysis of controlled clinical trials", BMC Infect Dis, 11, pp.165~ (2011)
  38. Cooksley WG, "Peginterferon alpha-2a(40 kDa) : an advance in the treatment of hepatitis B e antigen-positive chronic hepatitis B", J Viral Hepat, 10, pp.298~305 (2003)
  39. Moucari R, "Early serum HBsAg drop : a strong predictor of sustained virological response to pegylated interferon alfa-2a in HBeAg-negative patients", Hepatology, 49, pp.1151~1157 (2009)
  40. Chang TT, "Entecavir treatment for up to 5 years in patients with hepatitis B e antigen-positive chronic hepatitis B", Hepatology, 51, pp.422~430 (2010)
  41. Liu Y, "No detectable resistance to tenofovir disoproxil fumarate in HBeAg+and HBeAg-patients with chronic hepatitis B after 8 years of treatment", J Viral Hepat, 24, pp.68~74 (2017)
  42. Yim HJ, "Options for the management of antiviral resistance during hepatitis B therapy : reflections on battles over a decade", Clin Mol Hepatol, 19, pp.195~209 (2013)
  43. Ahn SH, "Efficacy and safety of besifovir dipivoxil maleate compared with tenofovir disoproxil fumarate in treatment of chronic hepatitis B virus infection", Clin Gastroenterol Hepatol, 17, pp.1850~1859.e4 (2019)
  44. Agarwal K, "96 weeks treatment of tenofovir alafenamide vs. tenofovir disoproxil fumarate for hepatitis B virus infection", J Hepatol, 68, pp.672~681 (2018)
  45. Buti M, "Tenofovir alafenamide versus tenofovir disoproxil fumarate for the treatment of patients with HBeAg-negative chronic hepatitis B virus infection : a randomised, double-blind, phase 3, non-inferiority trial", Lancet Gastroenterol Hepatol, 1, pp.196~206 (2016)
  46. Yoon EL, "Comparison of clevudine and entecavir for treatment-naive patients with chronic hepatitis B virus infection : two-year follow-up data", J Clin Gastroenterol, 45, pp.893~899 (2011)
  47. Su QM, "Effects of telbivudine and entecavir for HBeAgpositive chronic hepatitis B : a meta-analysis", World J Gastroenterol, 18, pp.6290~6301 (2012)
  48. Tak WY, "Clinical, biochemical, and pathological characteristics of clevudineassociated myopathy", J Hepatol, 53, pp.261~266 (2010)
  49. Eun Hye Kim, "Two cases of telbivudine-induced myopathy in siblings with chronic hepatitis B", Clinical and Molecular Hepatology, 19(1), pp.82~86 (2013), 대한간학회[DOI]
  50. Choi J, "Risk of hepatocellular carcinoma in patients treated with entecavir vs tenofovir for chronic hepatitis B : a Korean nationwide cohort study", JAMA Oncol, 5, pp.30~36 (2019)
  51. Kim SU, "A multicenter study of entecavir vs. tenofovir on prognosis of treatmentnaïve chronic hepatitis B in South Korea", J Hepatol, 71, pp.456~464 (2019)
  52. Lee SW, "Comparison of tenofovir and entecavir on the risk of hepatocellular carcinoma and mortality in treatment-naïve patients with chronic hepatitis B in Korea : a large-scale, propensity score analysis", Gut, 69, pp.1301~1308 (2020)
  53. Yip TC, "Tenofovir is associated with lower risk of hepatocellular carcinoma than entecavir in patients with chronic HBV infection in China", Gastroenterology, 158, pp.215~225.e6 (2020)
  54. Toy M, "Cost-effectiveness and cost thresholds of generic and brand drugs in a national chronic hepatitis B treatment program in China", PLoS One, 10, pp.e0139876~ (2015)
  55. Kim DY, "Baracle®vs Baraclude® for 48 weeks in patients with treatment-naïve chronic hepatitis B : a comparison of efficacy and safety", Drug Des Devel Ther, 11, pp.3145~3152 (2017)
  56. Kim JH, "Lowlevel viremia and the increased risk of hepatocellular carcinoma in patients receiving entecavir treatment", Hepatology, 66, pp.335~343 (2017)
  57. Yim HJ, "Switching to tenofovir vs continuing entecavir for hepatitis B virus with partial virologic response to entecavir : a randomized controlled trial", J Viral Hepat, 25, pp.1321~1330 (2018)
  58. Park ES, "Identification of a quadruple mutation that confers tenofovir resistance in chronic hepatitis B patients", J Hepatol, 70, pp.1093~1102 (2019)
  59. Sheldon J, "Selection of hepatitis B virus polymerase mutations in HIVcoinfected patients treated with tenofovir", Antivir Ther, 10, pp.727~734 (2005)
  60. Yeon JE, "Resistance to adefovir dipivoxil in lamivudine resistant chronic hepatitis B patients treated with adefovir dipivoxil", Gut, 55, pp.1488~1495 (2006)
  61. Yim HJ, "Evolution of multi-drug resistant hepatitis B virus during sequential therapy", Hepatology, 44, pp.703~712 (2006)
  62. Lee S, "Tenofovir versus tenofovir plus entecavir for chronic hepatitis B with lamivudine resistance and entecavir resistance", J Viral Hepat, 24, pp.141~147 (2017)
  63. Lee HW, "Longterm efficacy of tenofovir disoproxil fumarate monotherapy for multidrug-resistant chronic HBV infection", Clin Gastroenterol Hepatol, 17, pp.1348~1355.e2 (2019)
  64. 이지원, "클레부딘 근육병증이 발생한 만성 B형간염 환자들에서 엔테카비어 전환 치료의 효과", 대한소화기학회지, 61(1), pp.30~36 (2013), 대한소화기학회
  65. Duarte-Rojo A, "Efficacy and safety of tenofovir disoproxil fumarate in patients with chronic hepatitis B", Therap Adv Gastroenterol, 3, pp.107~119 (2010)
  66. Lau GK, "Peginterferon alfa-2a, lamivudine, and the combination for HBeAg-positive chronic hepatitis B", N Engl J Med, 352, pp.2682~2695 (2005)
  67. Chen X, "Extended peginterferon alfa-2a(Pegasys)therapy in Chinese patients with HBeAgnegative chronic hepatitis B", J Med Virol, 86, pp.1705~1713 (2014)
  68. Lampertico P, "Randomised study comparing 48 and 96 weeks peginterferon α-2a therapy in genotype D HBeAg-negative chronic hepatitis B", Gut, 62, pp.290~298 (2013)
  69. Lee HW, "Lamivudine maintenance beyond one year after HBeAg seroconversion is a major factor for sustained virologic response in HBeAg-positive chronic hepatitis B", Hepatology, 51, pp.415~421 (2010)
  70. 김영집, "Durability after discontinuation of nucleos(t)ide therapy in chronic HBeAg negative hepatitis patients", Clinical and Molecular Hepatology, 19(3), pp.300~304 (2013), 대한간학회[DOI]
  71. Kang SH, "Antiviral response is not sustained after cessation of lamivudine treatment in chronic hepatitis B patients : a 10-year follow-up study", J Med Virol, 89, pp.849~856 (2017)
  72. Chen CH, "The role of hepatitis B surface antigen quantification in predicting HBsAg loss and HBV relapse after discontinuation of lamivudine treatment", J Hepatol, 61, pp.515~522 (2014)
  73. 이한아, "Hepatitis B surface antigen titer is a good indicator of durable viral response after entecavir off-treatment for chronic hepatitis B", Clinical and Molecular Hepatology, 22(3), pp.382~389 (2016), 대한간학회
  74. Terrault NA, "AASLD guidelines for treatment of chronic hepatitis B", Hepatology, 63, pp.261~283 (2016)
  75. Wu CY, "Association between nucleoside analogues and risk of hepatitis B virus–related hepatocellular carcinoma recurrence following liver resection", JAMA, 308, pp.1906~1914 (2012)
  76. Yin J, "Effect of antiviral treatment with nucleotide", nucleoside analogs on postoperative prognosis of hepatitis B virus-related hepatocellular carcinoma : a twostage longitudinal clinical study, 2013, pp.31, 3647~3655
  77. Kumada T, "Effect of nucleos(t)ide analogue therapy on hepatocarcinogenesis in chronic hepatitis B patients : a propensity score analysis", J Hepatol, 58, pp.427~433 (2013)
  78. Jang JW, "A randomized controlled study of preemptive lamivudine in patients receiving transarterial chemo-lipiodolization", Hepatology, 43, pp.233~240 (2006)
  79. Nagamatsu H, "Prophylactic lamivudine administration prevents exacerbation of liver damage in HBe antigen positive patients with hepatocellular carcinoma undergoing transhepatic arterial infusion chemotherapy", Am J Gastroenterol, 99, pp.2369~2375 (2004)
  80. Chen G, "Chronic hepatitis B virus infection and mortality from non-liver causes : results from the Haimen City cohort study", Int J Epidemiol, 34, pp.132~137 (2005)
  81. Marcucci F, "The association of hepatitis B virus infection with B-cell non-Hodgkin lymphoma-a review", Am J Blood Res, 2, pp.18~28 (2012)
  82. Hsu C, "Chemotherapy-induced hepatitis B reactivation in lymphoma patients with resolved HBV infection : a prospective study", Hepatology, 59, pp.2092~2100 (2014)
  83. Liu WP, "Hepatitis B virus reactivation after withdrawal of prophylactic antiviral therapy in patients with diffuse large B cell lymphoma", Leuk Lymphoma, 57, pp.1355~1362 (2016)
  84. Dong HJ, "Risk of hepatitis B virus(HBV)reactivation in non-Hodgkin lymphoma patients receiving rituximab-chemotherapy : a meta-analysis", J Clin Virol, 57, pp.209~214 (2013)
  85. Lau GK, "Early is superior to deferred preemptive lamivudine therapy for hepatitis B patients undergoing chemotherapy", Gastroenterology, 125, pp.1742~1749 (2003)
  86. Huang YH, "Randomized controlled trial of entecavir prophylaxis for rituximabassociated hepatitis B virus reactivation in patients with lymphoma and resolved hepatitis B", J Clin Oncol, 31, pp.2765~2772 (2013)
  87. Loomba R, "Hepatitis B reactivation associated with immune suppressive and biological modifier therapies : current concepts, management strategies, and future directions", Gastroenterology, 152, pp.1297~1309 (2017)
  88. Söderström A, "Hepatitis B virus DNA during pregnancy and post partum : aspects on vertical transmission", Scand J Infect Dis, 35, pp.814~819 (2003)
  89. ter Borg MJ, "Exacerbation of chronic hepatitis B infection after delivery", J Viral Hepat, 15, pp.37~41 (2008)
  90. Chang CY, "Serum alanine aminotransferase and hepatitis B DNA flares in pregnant and postpartum women with chronic hepatitis B", Am J Gastroenterol, 111, pp.1410~1415 (2016)
  91. van Zonneveld M, "Lamivudine treatment during pregnancy to prevent perinatal transmission of hepatitis B virus infection", J Viral Hepat, 10, pp.294~297 (2003)
  92. Han GR, "A prospective and open-label study for the efficacy and safety of telbivudine in pregnancy for the prevention of perinatal transmission of hepatitis B virus infection", J Hepatol, 55, pp.1215~1221 (2011)
  93. Chen HL, "Efficacy of maternal tenofovir disoproxil fumarate in interrupting mother-toinfant transmission of hepatitis B virus", Hepatology, 62, pp.375~386 (2015)
  94. Pan CQ, "Tenofovir to prevent hepatitis B transmission in mothers with high viral load", N Engl J Med, 374, pp.2324~2334 (2016)
  95. Hyun MH, "Systematic review with meta-analysis : the efficacy and safety of tenofovir to prevent mother-to-child transmission of hepatitis B virus", Aliment Pharmacol Ther, 45, pp.1493~1505 (2017)
  96. Benaboud S, "Concentrations of tenofovir and emtricitabine in breast milk of HIV-1-infected women in Abidjan, Cote d’Ivoire, in the ANRS 12109TEmAA study, step 2", Antimicrob Agents Chemother, 55, pp.1315~1317 (2011)
  97. Wang CY, "Acute liver failure caused by severe acute hepatitis B: a case series from a multi-center investigation", Ann Clin Microbiol Antimicrob, 13, pp.23~ (2014)
  98. Miyake Y, "Lamivudine treatment improves the prognosis of fulminant hepatitis B", Intern Med, 47, pp.1293~1299 (2008)

관련 논문AI추천

Management of Chronic Hepatitis B with Nucleoside or Nucleotide Analogues: A Review of Current Guidelines유병철, 최문석거트앤리버 소화기연관학회협의회 · Gut and Liver2010 · 제4권 제1호Current Nucleos(t)ide Analogue Therapy for Chronic Hepatitis B조성원, Jae Youn Cheong, Soon Sun Kim거트앤리버 소화기연관학회협의회 · Gut and Liver2011 · 제5권 제3호Update on the treatment navigation for functional cure of chronic hepatitis B: Expert consensus 2.0Apichat Kaewdech, Di Wu, Fengmin Lu, Fu-sheng Wang, Guiqiang Wang, Hong Ren, Jia-Horng Kao, Junqi Niu, Man-Fung Yuen, Meifang Han, Motoyuki Otsuka, Patrick T.F. Kennedy, Paul Yien Kwo, Peng Hu, Qin Ning, Sainan Shu, Sang Hoon Ahn, Teerha Piratvisuth, Weiming Yan, Wenhong Zhang, Wenhui Li, Xiaojing Wang, Yasuhito Tanaka, Young-Suk Lim, Zhenghong Yuan, Zhiliang Gao대한간학회 · Clinical and Molecular Hepatology2025 · 제31권 제1호만성 B형간염 진료지침 업데이트안지현대한내과학회 · 대한내과학회지2022 · 제97권 제6호Management of chronic hepatitis B patients in immunetolerant phase: what latest guidelines recommendGrace Lai-Hung Wong대한간학회 · Clinical and Molecular Hepatology2018 · 제24권 제2호Safety considerations for withdrawal of nucleos(t)ide analogues in patients with chronic hepatitis B: First, do no harmCheng-Hao Tseng, Jia-Horng Kao, Yao-Chun Hsu대한간학회 · Clinical and Molecular Hepatology2023 · 제29권 제4호

이 간행물의 다른 논문 (39건)

Evidence-based clinical advice for nutrition and dietary weight loss strategies for the management of NAFLD and NASHRohit Loomba, Theresa J. Hydes, Sujan Ravi, Meagan E. Graypp. 383-400Liver graft from donation after circulatory death donor: Real practice to improve graft viabilityKoji Hashimotopp. 401-410Beneficial effect of anti-diabetic drugs for nonalcoholic fatty liver diseaseKyung-Soo Kim, Byung-Wan Leepp. 430-443Managing liver cirrhotic complications: Overview of esophageal and gastric varicesCosmas Rinaldi Adithya Lesmana, Monica Raharjo, Rino A. Ganipp. 444-460Precision medicine in nonalcoholic fatty liver disease: New therapeutic insights from genetics and systems biologySilvia Sookoian, Carlos J. Pirolapp. 461-475
원문 보기